We believe that human immortality is a matter of technological advances.
Printivo exists to push the boundaries of biomedical science and to come up with solutions via 3D-bioprinting.
We are designing 3D human bone tissue for the purposes in-vitro efficacy and toxicity assays. Printivo is providing pharmaceutical companies with bone tissue graft on demand that can be used for drug testing in pre-clinical trials.
We use our own 3D-bioprinting pneumatic extrusion technology. Our bioprinter EVE is perfectly designed for ultimate synergy with ADAM, our bioink formulas.
We work on creating and optimizing the microarchitecture of our tissue constructs. We monitor and enhance its cell vitality rates and cellular interactions interactions to fully mimic the native conditions of human tissues.
Printivo works with several cell lines, including stem cells. We differentiate the lines to sufficient maturity and examine their protein production and activity.
We have developed a variety of bioink formulas, capable to sustain cellular life. The main ingredient is collagen with a variety of supplementary synthetic and natural polymers.
fully functional 3D-bioprinted human organ is a matter of time.
Our technology enables us to create native-like micro-architecture of the bone tissue with surpassing accuracy on the details.
Printivo is providing pharmaceutical companies with bone tissue graft on demand that can be used for drug testing in pre-clinical trials.
Our Bone tissue model we can easily represent the dimensional complexity of a native human tissue and cell-to-cell interactions.
As a supplementary to the animal models (and replacing them all in future), our Bone graft can provide more accurate and sophisticated data of how the new molecule affect the cell and predict its toxicity.
Artificial human tissues can provide that information and fill the gap between Pre-Clinical and Clinical phases of the whole Drug Development value chain.
Accelerator Startup Sofia
Иновативно Предприятие на годината
CIDIC Award
Betapitch Global finalists
CESAwards National winners and Regional finalists
We are a team of 11 young professionals. The main strength of our team is that it's comprised of highly educated and experienced members in the field of medicine (the CEO is MD), biotechnologies and engineering – 2 postDocs and 2 of them PhDs already.
Founder and CTO
Founder and CEO
© PRINTIVO 2019